T-cell activation is an immune correlate of risk in BCG vaccinated infants

Nature Communications

Volumn 7, Issue , 2016, Pages

  Fletcher, Helen A ^a,b   Snowden, Margaret A ^c   Landry, Bernard ^c   Rida, Wasima ^d   Satti, Iman ^a   Harris, Stephanie A ^a   Matsumiya, Magali ^a   Tanner, Rachel ^a   Oshea, Matthew K ^a   Dheenadhayalan, Veerabadran ^c   Bogardus, Leah ^c   Stockdale, Lisa ^a,b   Marsay, Leanne ^e   Chomka, Agnieszka ^f   Harrington Kandt, Rachel ^a   Manjaly Thomas, Zita Rose ^a   Naranbhai, Vivek ^a   Stylianou, Elena ^a   Darboe, Fatoumatta ^g   Penn Nicholson, Adam ^g   Nemes, Elisa ^g   Hatheril, Mark ^g   Hussey, Gregory ^g   Mahomed, Hassan ^g   Tameris, Michele ^g   McClain, J Bruce ^c   Evans, Thomas G ^c   Hanekom, Willem A ^g   Scriba, Thomas J ^g   McShane, Helen ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c AERAS   (United States)

^d Biostatistics Consultant   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HLA DR ANTIGEN; IMMUNOGLOBULIN G; PLACEBO;

BACTERIUM; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; IMMUNE RESPONSE; PROTEIN; RISK FACTOR; TUBERCULOSIS; VACCINE;

ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; HUMAN; INFANT; MYCOBACTERIUM BOVIS BCG; RISK; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ADOLESCENT; ANTIBODY PRODUCTION; BLOOD; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; IMMUNITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; VACCINATION;

MYCOBACTERIUM TUBERCULOSIS;

ADOLESCENT; ANTIBODY FORMATION; BCG VACCINE; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; HLA-DR ANTIGENS; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; INFANT; LOGISTIC MODELS; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; PLACEBOS; RISK FACTORS; TIME FACTORS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 84964397293     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11290     Document Type: Article

References (40)

1. Hawkridge, A. et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337 a2052 (2008).
2. Altare, F. et al. Impairment of mycobacterial immunity in human interleukin- 12 receptor deficiency. Science 280, 1432-1435 (1998)
3. Jouanguy, E. et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335, 1956-1961 (1996)
4. Lichtenauer-Kaligis, E. G. et al. Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency. Eur. J. Immunol. 33 59-69 (2003)
5. Newport, M. J. et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335, 1941-1949 (1996)
6. Picard, C. et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am. J. Hum. Genet. 70, 336-348 (2002)
7. Harries, A. D. et al. The HIV-associated tuberculosis epidemic-when will we act? Lancet 375, 1906-1919 (2010)
8. Cooper, A. M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178, 2243-2247 (1993)
9. Flynn, J. L. et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249-2254 (1993)
10. Brennan, M. J., Stone, M. R. & Evans, T. A rational vaccine pipeline for tuberculosis. Int. J. Tuberc. Lung Dis. 16, 1566-1573 (2012)
11. Kagina, B. M. et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182 1073-1079 (2010)
12. Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised placebo-controlled phase 2b trial. Lancet 381, 1021-1028 (2013)
13. Hochberg, Y. & Benjamini, Y. More powerful procedures for multiple significance testing. Stat. Med. 9, 811-818 (1990)
14. Mahomed, H. et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Int. J. Tuberc. Lung Dis. 15 331-336 (2011)
15. Giorgi, J. V. & Detels, R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin. Immunol. Immunopathol. 52, 10-18 (1989)
16. Karim, R. et al. Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS 27. 1473-1481 (2013).
17. Liu, Z. et al. Elevated CD38 antigen expression on CD8 T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4 cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 16, 83-92 (1997)
18. Hazenberg, M. D. et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17, 1881-1888 (2003)
19. Soares, A. P. et al. Longitudinal changes in CD4() T-cell memory responses induced by BCG vaccination of newborns. J. Infect. Dis. 207, 1084-1094 (2013)
20. Wittkop, L. et al. Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. J. Infect. Dis. 207, 622-627 (2013)
21. Evans, T. G. et al. Expansion of the CD57 subset of CD8 T cells in HIV-1 infection is related to CMV serostatus. AIDS 13, 1139-1141 (1999)
22. Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37-47 (2015)
23. Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin. Infect. Dis. 58, 470-480 (2014)
24. de Almeida, A. S., Fiske, C. T., Sterling, T. R. & Kalams, S. A. Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin. Vaccine. Immunol. 19 45-52 (2012)
25. Wergeland, I., Assmus, J. & Dyrhol-Riise, A. M. T regulatory cells and immune activation in Mycobacterium tuberculosis infection and the effect of preventive therapy. Scand. J. Immunol. 73, 234-242 (2011)
26. Sansoni, P. et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 82, 2767-2773 (1993)
27. Rea, I. M., McNerlan, S. E. & Alexander, H. D. CD69, CD25, and HLA-DR activation antigen expression on CD3 lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging. Exp. Gerontol. 34 79-93 (1999)
28. Kaufman, M. D. Do microbes with peptides mimicking myelin cause multiple sclerosis if the T cell response to their unique peptides is limited? J. Theor. Biol. 193, 691-708 (1998)
29. Messele, T. et al. Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin. Exp Immunol. 115, 443-450 (1999)
30. Muyanja, E. et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J. Clin. Invest. 124, 3147-3158 (2014)
31. Zak, D. E. et al. for other members of the ACS and GC6-74 cohort study teams. A prospective blood RNA signature for tuberculosis disease risk. Lancet http://dx. doi. org/10. 1016/S0140-6736(15)01316-1 (23 March 2016)
32. Cannon, M. J. Congenital cytomegalovirus (CMV) epidemiology and awareness. J. Clin. Virol. 46(Suppl 4)): S6-S-10 (2009)
33. Staras, S. A. et al. Influence of sexual activity on cytomegalovirus seroprevalence in the United States, 1988-1994. Sex Transm. Dis. 35, 472-479 (2008)
34. Hawkridge, T. et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198, 544-552 (2008)
35. McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10, 1240-1244 (2004)
36. Scriba, T. J. et al. Dose-finding study of the novel tuberculosis vaccine. MVA85A, in healthy BCG-vaccinated infants. J. Infect. Dis. 203, 1832-1843 (2011)
37. Beyazova, U., Rota, S., Cevheroglu, C. & Karsligil, T. Humoral immune response in infants after BCG vaccination. Tuber. Lung Dis. 76, 248-253 (1995)
38. Knight, G. M. et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc. Natl Acad. Sci. USA 111.15520-15525 (2014).
39. Harris, S. A. et al. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A. Clin. Vaccine Immunol. 21, 1005-1011 (2014)
40. Yang, L. & Tsiatis, A. A. Efficiency study of estimators for a treatment effect in a pretest-posttest trial. Am. Stat. 55, 314-321 (2001)